1
|
Fritz C, Jaeger D, Luo Y, Lardenois E, Badat B, Roquet FE, Rigollot M, Kimmoun A, Tran N'G, Richard JCM, Chouihed T, Levy B. IMPACT OF DIFFERENT VENTILATION STRATEGIES ON GAS EXCHANGES AND CIRCULATION DURING PROLONGED MECHANICAL CARDIO-PULMONARY RESUSCITATION IN A PORCINE MODEL. Shock 2022; 58:119-127. [PMID: 34710880 DOI: 10.1097/shk.0000000000001880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
ABSTRACT Background: Optimal ventilation during cardio-pulmonary resuscitation (CPR) is still controversial. Ventilation is expected to provide sufficient arterial oxygen content and adequate carbon dioxide removal, while minimizing the risk of circulatory impairment. The objective of the present study was to compare three ventilation strategies in a porcine model during mechanical continuous chest compressions (CCC) according to arterial oxygenation and hemodynamic impact. Method: Ventricular fibrillation was induced and followed by five no-flow minutes and thirty low-flow minutes resuscitation with mechanical-CCC without vasopressive drugs administration. Three groups of eight Landras pig were randomized according to the ventilation strategy: 1. Standard nonsynchronized volume-control mode (SD-group); 2. synchronized bilevel pressure-controlled ventilation (CPV-group); 3. continuous insufflation with Boussignac Cardiac-Arrest Device (BC-group). We assessed 1. arterial blood gases, 2. macro hemodynamics, 3. tissular cerebral macro and micro-circulation and 4. airway pressure, minute ventilation at baseline and every 5 minutes during the protocol. Results: Arterial PaO2 level was higher at each measurement time in SD-group (>200 mm Hg) compare to CPV-group and BC-group ( P < 0.01). In BC-group, arterial PaCO2 level was significantly higher (>90mm Hg) than in SD and CPV groups ( P < 0.01). There was no difference between groups concerning hemodynamic parameters, cerebral perfusion and microcirculation. Conclusion: Ventilation modalities in this porcine model of prolonged CPR influence oxygenation and decarboxylation without impairing circulation and cerebral perfusion. Synchronized bi-level pressure-controlled ventilation' use avoid hyperoxia and was as efficient as asynchronized volume ventilation to maintain alveolar ventilation and systemic perfusion during prolonged CPR.
Collapse
|
2
|
Gauchotte G, Bochnakian A, Campoli P, Lardenois E, Brix M, Simon E, Colomb S, Martrille L, Peyron PA. Myeloperoxydase and CD15 With Glycophorin C Double Staining in the Evaluation of Skin Wound Vitality in Forensic Practice. Front Med (Lausanne) 2022; 9:910093. [PMID: 35665361 PMCID: PMC9156797 DOI: 10.3389/fmed.2022.910093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Accepted: 04/25/2022] [Indexed: 12/01/2022] Open
Abstract
Background The determination of skin wound vitality based on tissue sections is a challenge for the forensic pathologist. Histology is still the gold standard, despite its low sensitivity. Immunohistochemistry could allow to obtain a higher sensitivity. Upon the candidate markers, CD15 and myeloperoxidase (MPO) may allow to early detect polymorphonuclear neutrophils (PMN). The aim of this study was to evaluate the sensitivity and the specificity of CD15 and MPO, with glycophorin C co-staining, compared to standard histology, in a series of medicolegal autopsies, and in a human model of recent wounds. Methods Twenty-four deceased individuals with at least one recent open skin wound were included. For each corpse, a post-mortem wound was performed in an uninjured skin area. At autopsy, a skin sample from the margins of each wound and skin controls were collected (n = 72). Additionally, the cutaneous surgical margins of abdominoplasty specimens were sampled as a model of early intravital stab wound injury (scalpel blade), associated with post-devascularization wounds (n = 39). MPO/glycophorin C and CD15/glycophorin C immunohistochemical double staining was performed. The number of MPO and CD15 positive cells per 10 high power fields (HPF) was evaluated, excluding glycophorin C—positive areas. Results With a threshold of at least 4 PMN/10 high power fields, the sensitivity and specificity of the PMN count for the diagnostic of vitality were 16 and 100%, respectively. With MPO/glycophorin C as well as CD15/glycophorin C IHC, the number of positive cells was significantly higher in vital than in non-vital wounds (p < 0.001). With a threshold of at least 4 positive cells/10 HPF, the sensitivity and specificity of CD15 immunohistochemistry were 53 and 100%, respectively; with the same threshold, MPO sensitivity and specificity were 28 and 95%. Conclusion We showed that combined MPO or CD15/glycophorin C double staining is an interesting and original method to detect early vital reaction. CD15 allowed to obtain a higher, albeit still limited, sensitivity, with a high specificity. Confirmation studies in independent and larger cohorts are still needed to confirm its accuracy in forensic pathology.
Collapse
Affiliation(s)
- Guillaume Gauchotte
- Department of Biopathology, CHRU-ICL, CHRU Nancy, Vandoeuvre-lès-Nancy, France.,Faculty of Medicine, Université de Lorraine, Vandoeuvre-lès-Nancy, France.,Department of Legal Medicine, CHRU Nancy, Vandoeuvre-lès-Nancy, France.,INSERM U1256, NGERE, Vandoeuvre-lès-Nancy, France.,Centre de Ressources Biologiques, BB-0033-00035, CHRU, Nancy, France
| | - Agathe Bochnakian
- Department of Biopathology, CHRU-ICL, CHRU Nancy, Vandoeuvre-lès-Nancy, France.,Faculty of Medicine, Université de Lorraine, Vandoeuvre-lès-Nancy, France
| | - Philippe Campoli
- Department of Biopathology, CHRU-ICL, CHRU Nancy, Vandoeuvre-lès-Nancy, France.,Faculty of Medicine, Université de Lorraine, Vandoeuvre-lès-Nancy, France
| | - Emilie Lardenois
- Department of Biopathology, CHRU-ICL, CHRU Nancy, Vandoeuvre-lès-Nancy, France.,Faculty of Medicine, Université de Lorraine, Vandoeuvre-lès-Nancy, France
| | - Muriel Brix
- Faculty of Medicine, Université de Lorraine, Vandoeuvre-lès-Nancy, France.,Department of Maxillofacial and Plastic Surgery, CHRU, Nancy, France
| | - Etienne Simon
- Faculty of Medicine, Université de Lorraine, Vandoeuvre-lès-Nancy, France.,Department of Maxillofacial and Plastic Surgery, CHRU, Nancy, France
| | - Sophie Colomb
- Department of Forensic Medicine, CHU Montpellier, University of Montpellier, Montpellier, France.,EDPFM, University of Montpellier, Département de Médecine Légale, Montpellier, France
| | - Laurent Martrille
- Department of Forensic Medicine, CHU Montpellier, University of Montpellier, Montpellier, France.,EDPFM, University of Montpellier, Département de Médecine Légale, Montpellier, France
| | - Pierre-Antoine Peyron
- Department of Forensic Medicine, CHU Montpellier, University of Montpellier, Montpellier, France.,IRMB, INM, University of Montpellier, INSERM, CHU Montpellier (LBPC-PPC), Montpellier, France
| |
Collapse
|
3
|
Fumet JD, Lardenois E, Ray-Coquard I, Harter P, Joly F, Canzler U, Truntzer C, Tredan O, Liebrich C, Lortholary A, Pissaloux D, Leary A, Pfisterer J, Eeckhoutte A, Hilpert F, Fabbro M, Caux C, Alexandre J, Houlier A, Sehouli J, Sohier E, Kimmig R, Dubois B, Spaeth D, Treilleux I, Frenel JS, Herwig U, Le Saux O, Bendriss-Vermare N, du Bois A. Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial. Cancers (Basel) 2022; 14:cancers14051189. [PMID: 35267497 PMCID: PMC8909387 DOI: 10.3390/cancers14051189] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 02/21/2022] [Accepted: 02/22/2022] [Indexed: 02/05/2023] Open
Abstract
Background: Following disappointing results with PD-1/PD-L1 inhibitors in ovarian cancer, it is essential to explore other immune targets. The aim of this study is to describe the tumor immune microenvironment (TME) according to genomic instability in high grade serous ovarian carcinoma (HGSOC) patients receiving primary debulking surgery followed by carboplatin-paclitaxel chemotherapy +/− nintedanib. Methods: 103 HGSOC patients’ tumor samples from phase III AGO-OVAR-12 were analyzed. A comprehensive analysis of the TME was performed by immunohistochemistry on tissue microarray. Comparative genomic hybridization was carried out to evaluate genomic instability signatures through homologous recombination deficiency (HRD) score, genomic index, and somatic copy number alterations. The relationship between genomic instability and TME was explored. Results: Patients with high intratumoral CD3+ T lymphocytes had longer progression-free survival (32 vs. 19.6 months, p = 0.009) and overall survival (OS) (median not reached). High HLA-E expression on tumor cells was associated with a longer OS (median OS not reached vs. 52.9 months, p = 0.002). HRD profile was associated with high HLA-E expression on tumor cells and an improved OS. In the multivariate analysis, residual tumor, intratumoral CD3, and HLA-E on tumor cells were more predictive than other parameters. Conclusions: Our results suggest HLA-E/CD94-NKG2A/2C is a potential immune target particularly in the HRD positive ovarian carcinoma subgroup.
Collapse
Affiliation(s)
- Jean-David Fumet
- GINECO & Department of Medical Oncology, Center GF Leclerc, 1 rue du Professeur Marion, 21000 Dijon, France
- Platform of Transfer in Cancer Biology, 21079 Dijon, France;
- University of Bourgogne-Franche-Comté, 21000 Dijon, France
- Correspondence: (J.-D.F.); (N.B.-V.)
| | - Emilie Lardenois
- Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, “Cancer Immune Surveillance and Therapeutic Targeting” Team, 69000 Lyon, France; (E.L.); (I.R.-C.); (C.C.); (B.D.); (O.L.S.)
- Leon Berard Center, Department of Pathology, 69000 Lyon, France; (D.P.); (A.H.); (I.T.)
| | - Isabelle Ray-Coquard
- Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, “Cancer Immune Surveillance and Therapeutic Targeting” Team, 69000 Lyon, France; (E.L.); (I.R.-C.); (C.C.); (B.D.); (O.L.S.)
- GINECO & Medical Oncology Department, Centre Léon Bérard, 28, rue Laennec, Université Claude Bernard Lyon 1, 69008 Lyon, France;
| | - Philipp Harter
- AGO & Department of Gynecology and Gynecologic Oncology, Evang. Kliniken Essen-Mitte, 45136 Essen, Germany;
| | - Florence Joly
- GINECO & Department of Medical Oncology, Baclesse Cancer Center, 14118 Caen, France;
| | - Ulrich Canzler
- AGO & Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany & National Center for Tumor Diseases (NCT), Partner Site Dresden, 01307 Dresden, Germany;
| | - Caroline Truntzer
- Platform of Transfer in Cancer Biology, 21079 Dijon, France;
- Genetic and Immunology Medical Institute (GIMI), 21000 Dijon, France
- UMR INSERM 1231, 21000 Dijon, France
| | - Olivier Tredan
- GINECO & Medical Oncology Department, Centre Léon Bérard, 28, rue Laennec, Université Claude Bernard Lyon 1, 69008 Lyon, France;
| | - Clemens Liebrich
- AGO & Klinikum Wolfsburg, amO—Interdisziplinäres ambulantes Onkologiezentrum am Klieversberg, Sauerbruchstrasse 7, 38840 Wolfsburg, Germany;
| | - Alain Lortholary
- GINECO & Confluent Private Hospital, Institut de Cancérologie Catherine de Sienne, 44200 Nantes, France;
| | - Daniel Pissaloux
- Leon Berard Center, Department of Pathology, 69000 Lyon, France; (D.P.); (A.H.); (I.T.)
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, 69000 Lyon, France
| | - Alexandra Leary
- GINECO & Medical Oncology Department, Institut Gustave Roussy, 94805 Villejuif, France;
| | - Jacobus Pfisterer
- AGO & Zentrum für Gynäkologische Onkologie, Herzog-Friedrich-Str. 21, 24103 Kiel, Germany;
| | - Alexandre Eeckhoutte
- INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.m) PSL Research University, Institut Curie, 75005 Paris, France;
| | - Felix Hilpert
- AGO & Krankenhaus Jerusalem, Moorkamp 2-6, Onkologische Tagesklinik, 20357 Hamburg, Germany;
| | - Michel Fabbro
- GINECO & ICM Val d’Aurelle, oncologie médicale, 208, Avenue des Apothicaires, 34298 Montpellier, France;
| | - Christophe Caux
- Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, “Cancer Immune Surveillance and Therapeutic Targeting” Team, 69000 Lyon, France; (E.L.); (I.R.-C.); (C.C.); (B.D.); (O.L.S.)
- Laboratory for Immunotherapy of Cancer of Lyon (LICL), Centre Léon Bérard, 69000 Lyon, France
| | - Jérôme Alexandre
- GINECO & Medical Oncology Department, Hopital Cochin, 75014 Paris, France;
| | - Aurélie Houlier
- Leon Berard Center, Department of Pathology, 69000 Lyon, France; (D.P.); (A.H.); (I.T.)
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, 69000 Lyon, France
| | - Jalid Sehouli
- AGO & Charité, Medical University of Berlin, Department of Gynecology with Center of Oncological Surgery, Augustenburger Platz 1, 13353 Berlin, Germany;
| | - Emilie Sohier
- Synergie Lyon Cancer, Bio-Informatics Platform, 69000 Lyon, France;
| | - Rainer Kimmig
- AGO & West-German Cancer Center, Department of Gynecology and Obstetrics, University of Duisburg-Essen Germany, 45136 Essen, Germany;
| | - Bertrand Dubois
- Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, “Cancer Immune Surveillance and Therapeutic Targeting” Team, 69000 Lyon, France; (E.L.); (I.R.-C.); (C.C.); (B.D.); (O.L.S.)
- Laboratory for Immunotherapy of Cancer of Lyon (LICL), Centre Léon Bérard, 69000 Lyon, France
| | - Dominique Spaeth
- GINECO & Medical Oncology Department Centre d’Oncologie de Gentilly, 54000 Nancy, France;
| | - Isabelle Treilleux
- Leon Berard Center, Department of Pathology, 69000 Lyon, France; (D.P.); (A.H.); (I.T.)
| | - Jean-Sébastien Frenel
- GINECO & Medical Oncology Department Institut de cancerologie de l’Ouest site René Gauducheau, 44800 Saint Herblain, France;
| | - Uwe Herwig
- AGO & Albertinen-Krankenhaus, Department Gynecology, Süntelstraße 11a, 22457 Hamburg, Germany;
| | - Olivia Le Saux
- Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, “Cancer Immune Surveillance and Therapeutic Targeting” Team, 69000 Lyon, France; (E.L.); (I.R.-C.); (C.C.); (B.D.); (O.L.S.)
- GINECO & Medical Oncology Department, Centre Léon Bérard, 28, rue Laennec, Université Claude Bernard Lyon 1, 69008 Lyon, France;
| | - Nathalie Bendriss-Vermare
- Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, “Cancer Immune Surveillance and Therapeutic Targeting” Team, 69000 Lyon, France; (E.L.); (I.R.-C.); (C.C.); (B.D.); (O.L.S.)
- Laboratory for Immunotherapy of Cancer of Lyon (LICL), Centre Léon Bérard, 69000 Lyon, France
- Correspondence: (J.-D.F.); (N.B.-V.)
| | - Andreas du Bois
- AGO & Evangelische Kliniken Essen Mitte (KEM), 45136 Essen, Germany;
| |
Collapse
|
4
|
Delhomme C, Mariano-Bourin M, Melgar E, Bologna S, Lardenois E, Poreaux C, Granel-Brocard F, Schmutz JL, Bursztejn AC. Mélanome métastatique et lymphome malin non hodgkinien : association rare, diagnostic complexe mais prise en charge commune possible. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
5
|
Barbé J, Escobar G, Marzouki-Zerouali A, Lardenois E, Schmutz JL, Bursztejn AC. Disseminated indolent ALK-positive primary cutaneous anaplastic large cell lymphoma (C-ALCL) lasting for 10 years. Int J Dermatol 2020; 60:e146-e147. [PMID: 33249555 DOI: 10.1111/ijd.15324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/21/2020] [Revised: 10/08/2020] [Accepted: 11/03/2020] [Indexed: 11/26/2022]
Affiliation(s)
- Jordane Barbé
- Dermatology Department, University Hospital of Nancy, Vandoeuvre les Nancy, France
| | - Gabriela Escobar
- Dermatology Department, University Hospital of Nancy, Vandoeuvre les Nancy, France
| | | | - Emilie Lardenois
- Pathologist Department, University Hospital of Nancy, Vandoeuvre les Nancy, France
| | - Jean-Luc Schmutz
- Dermatology Department, University Hospital of Nancy, Vandoeuvre les Nancy, France
| | | |
Collapse
|
6
|
Eberhardt A, Blanc E, Lardenois E, Renaudineau S, Herbulot J, Dumont B, Durand I, Charrier E, Schmitt P, Girard JP, Marçais A, Walzer T, Caux C, Bendriss-Vermare N. Abstract B84: Decipher the role of IL-33 as an activator of NK cells’ antitumor activity. Cancer Immunol Res 2020. [DOI: 10.1158/2326-6074.tumimm18-b84] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Interleukin (IL)-33 is an alarmin belonging to the IL-1 family. Through its receptor ST2, IL-33 promotes both type 1 and type 2 immune responses, depending on the type of responding cells and the microenvironment in damaged tissues. Consistently, paradoxical roles of IL-33 have been reported in the context of cancer. These observations prompted us to investigate i) the expression of IL-33/ST2 in breast tumors and ii) the role of IL-33/ST2 in NK cell activation in physiologic and tumor contexts. Using immunohistochemistry (IHC) and transcriptomic analyses, we observed that IL-33 is expressed at higher levels in ductal carcinoma in situ (DCIS) compared to invasive breast cancer (IBC), especially in the stroma and in luminal BC subtype. In situ, IL-33 was mainly detected in endothelial cells and at lower extent in scattered cells within the stroma of breast tumors. Furthermore, we unraveled a new pathway for NK cells’ activation where IL-12 upregulates ST2 on human NK cells, which in turn become responsive to IL-33 by secreting high levels of IFN-γ and increasing their cytotoxic activity. This effect was specific to a subset of human CD56dim NK cells (20%) and was dependent on STAT-4 phosphorylation. In mice, we also observed a strong activation of spleen NK cell by IL-33 in combination with IL-12 in vitro. Finally, using IL-33ko mice, preliminary results show a contribution of endogenous IL-33 in the prevention of experimental lung metastasis development following B16 iv injection in therapeutic settings using exogenous administration of IL-12. Following up on these results, our aim is now to i) better characterize IL-33-responsive NK cells subpopulation in blood, ii) understand why human CD56bright NK cells do not upregulate ST2 despite response to IL-12 by phosphorylating STAT-4, iii) characterize NK cells’ response to IL-33 in human breast tumors, iv) evaluate ST2 expression by immune cells infiltrating breast and ovarian tumors, and v) confirm the activating role of IL-33 on NK cells’ biology in tumor models in vivo. All together, our observations are in favor of an NK-mediated antitumor role of IL-33 that we are currently pursuing as a potential novel therapeutic strategy in cancer.
Citation Format: Anais Eberhardt, Elena Blanc, Emilie Lardenois, Sarah Renaudineau, Jennifer Herbulot, Benoit Dumont, Isabelle Durand, Emilie Charrier, Pauline Schmitt, Jean-Philippe Girard, Antoine Marçais, Thierry Walzer, Christophe Caux, Nathalie Bendriss-Vermare. Decipher the role of IL-33 as an activator of NK cells’ antitumor activity [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2018 Nov 27-30; Miami Beach, FL. Philadelphia (PA): AACR; Cancer Immunol Res 2020;8(4 Suppl):Abstract nr B84.
Collapse
Affiliation(s)
| | - Elena Blanc
- 1CRCL UMR INSERM 1052 CNRS 5286, Lyon, France,
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Barbé J, Lardenois E, Schmutz JL, Bursztejn AC. Une forme historique de lymphome cutané anaplasique à grandes cellules ALK positif. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
8
|
Pouget C, Hergalant S, Lardenois E, Lacomme S, Houlgatte R, Carpentier C, Dehais C, Rech F, Taillandier L, Sanson M, Appay R, Colin C, Figarella-Branger D, Battaglia-Hsu SF, Gauchotte G. Ki-67 and MCM6 labeling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1-mutant and 1p/19q-codeleted: a multicenter study from the French POLA network. Brain Pathol 2019; 30:465-478. [PMID: 31561286 DOI: 10.1111/bpa.12788] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2019] [Accepted: 09/19/2019] [Indexed: 12/14/2022] Open
Abstract
Anaplastic oligodendroglioma (AO), IDH-mutant and 1p/19q codeleted (IDHmut+/1p19qcodel), is a high-grade glioma with only limited prognostic markers. The primary objective of this study was to evaluate, by immunohistochemistry, the prognostic value of two proliferation markers, MCM6 and Ki-67, in a large series of IDHmut+/1p19qcodel AO included in the POLA ("Prise en charge des Oligodendrogliomes Anaplasiques") French national multicenter network. We additionally examined the transcriptome obtained from this series to understand the functional pathways dysregulated with the mRNA overexpression of these two markers. The labeling indices (LI) of MCM6 and Ki-67 were obtained via computer-assisted color image analyses on immunostained AO tissues of the cohort (n = 220). Furthermore, a subgroup of AO (n = 68/220) was used to perform transcriptomic analyses. A high LI of either MCM6 (≥50%) or Ki-67 (≥15%) correlated with shorter overall survival, both in univariate (P = 0.013 and P = 0.004, respectively) and multivariate analyses (P = 0.027; multivariate Cox model including age, mitotic index, MCM6 and Ki-67). MCM6 and Ki-67 LI also correlated with overall survival in an additional retrospective cohort of 30 grade II IDHmut+/1p19qcodel oligodendrogliomas. The prognostic value of MCM6 mRNA level was confirmed in The Cancer Genome Atlas (TCGA) IDHmut+/1p19qcodel gliomas. The transcriptomic approach revealed that high transcriptional expressions of MCM6 and MKI67 were both linked positively with cell cycle progression, DNA replication, mitosis, pro-neural phenotype as well as neurogenesis, and negatively with microglial cell activation, immune response, positive regulation of myelination, oligodendrocyte development, beta-amyloid binding and postsynaptic specialization. In conclusion, the overexpression of MCM6 and/or Ki-67 is independently associated to shorter overall survival in IDHmut+/1p19qcodel AO. These two easy-to-use and cost-effective markers could thus be used concurrently in routine pathology practice. Additionally, the transcriptomic analyses showed that AO with high proliferation index have down-regulated immune response and lower microglial cells activation, and bears pro-neural phenotype.
Collapse
Affiliation(s)
- Celso Pouget
- Department of Pathology, CHRU, Nancy, France.,INSERM U1256, NGERE, Faculté de Médecine de Nancy, Université de Lorraine, Vandoeuvre-lès-Nancy, France
| | - Sébastien Hergalant
- INSERM U1256, NGERE, Faculté de Médecine de Nancy, Université de Lorraine, Vandoeuvre-lès-Nancy, France
| | - Emilie Lardenois
- Department of Pathology, CHRU, Nancy, France.,INSERM U1256, NGERE, Faculté de Médecine de Nancy, Université de Lorraine, Vandoeuvre-lès-Nancy, France
| | - Stéphanie Lacomme
- Centre de Ressources Biologiques, CHRU, BB-0033-00035, Nancy, France
| | - Rémi Houlgatte
- INSERM U1256, NGERE, Faculté de Médecine de Nancy, Université de Lorraine, Vandoeuvre-lès-Nancy, France
| | - Catherine Carpentier
- Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM, F-75013, Paris, France
| | - Caroline Dehais
- AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, 75013, Paris, France
| | - Fabien Rech
- Department of Neurosurgery, CHRU, Nancy, France.,Institut des Neurosciences, INSERM U1051, Montpellier, France
| | | | - Marc Sanson
- Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM, F-75013, Paris, France.,AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, 75013, Paris, France.,Onconeurotek, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| | - Romain Appay
- Aix-Marseille Univ, CNRS, INP, Inst. Neurophysiopathol, Marseille, France.,AP-HM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie and Centre de Ressources Biologiques CRB-TBM, BB-0033-00097, Marseille, France
| | - Carole Colin
- Aix-Marseille Univ, CNRS, INP, Inst. Neurophysiopathol, Marseille, France
| | - Dominique Figarella-Branger
- Aix-Marseille Univ, CNRS, INP, Inst. Neurophysiopathol, Marseille, France.,AP-HM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie and Centre de Ressources Biologiques CRB-TBM, BB-0033-00097, Marseille, France
| | - Shyue-Fang Battaglia-Hsu
- INSERM U1256, NGERE, Faculté de Médecine de Nancy, Université de Lorraine, Vandoeuvre-lès-Nancy, France
| | - Guillaume Gauchotte
- Department of Pathology, CHRU, Nancy, France.,INSERM U1256, NGERE, Faculté de Médecine de Nancy, Université de Lorraine, Vandoeuvre-lès-Nancy, France.,Centre de Ressources Biologiques, CHRU, BB-0033-00035, Nancy, France
| |
Collapse
|
9
|
Violon F, Lardenois E, Grafiadis P, Martrille L, Gauchotte G. Fatal left coronary artery dissection due to blunt chest trauma: A case report and literature review. Med Sci Law 2019; 59:214-218. [PMID: 31248322 DOI: 10.1177/0025802419857629] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Blunt chest traumas can cause cardiac injuries and contusions. However, post-traumatic coronary artery dissections are quite uncommon. Here, we report the case of a 58-year-old woman who died suddenly 14 hours after a car accident. The macroscopic anomalies observed during the autopsy could not explain the death. However, microscopic examination revealed an acute left anterior descending coronary dissection, with a cleavage of the external layers of the media. The infiltration of polymorphonuclear neutrophils in the adventitia was a sign of the pre-mortem occurrence of this lesion and was compatible with the chronology of the accident. It was the only pathological finding that could explain the death, which was probably caused by a cardiac rhythm disorder triggered by acute ischaemia. We did not observe specific histological signs of cardiac necrosis, and we observed no significant atheroma, vasculitis or dysplasia in the left anterior descending coronary artery. We concluded that the dissection was secondary to the blunt chest trauma. Eleven case reports of lethal post-traumatic coronary dissection have been reported in the literature. Most of them involved male subjects aged <60 years old following a traffic accident, and were localised to the left coronary artery or one of its branches. Histological specific signs of myocardial ischaemia were present in only 33% of the cases. In this case, only microscopic examination could identify the dissection. This pathology may be underdiagnosed, and it highlights the necessity to undertake rigorous examination of the heart and coronary arteries following blunt chest trauma.
Collapse
Affiliation(s)
| | | | | | - Laurent Martrille
- Department of Legal Medicine, CHRU de Nancy, France
- Université de Lorraine, France
| | - Guillaume Gauchotte
- Department of Pathology, CHRU de Nancy, France
- Department of Legal Medicine, CHRU de Nancy, France
- Université de Lorraine, France
- INSERM U1256, France
- Centre de Ressources Biologiques, France
| |
Collapse
|
10
|
Yguel C, Clauzon D, Lacomme S, Lomazzi S, Lardenois E, Pouget C, Taillandier L, Rech F, Rigau V, Vignaud JM, Bauchet L, Gauchotte G. [Use of the PELICAN software for the creation and export of standardized pathology reports in central nervous system tumors: Example of meningiomas]. Ann Pathol 2019; 39:414-424. [PMID: 30853495 DOI: 10.1016/j.annpat.2019.01.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2018] [Revised: 01/24/2019] [Accepted: 01/25/2019] [Indexed: 12/01/2022]
Abstract
INTRODUCTION PELICAN ("Partager Efficacement en Laboratoire les Informations des Comptes rendus ANatomopathologiques") is a software, which generates standardized reports, and allows to automatically create a database. It has been used in central nervous system tumor pathology at the University Hospital of Nancy since 2014. The purpose of this article was to illustrate the use of this application for meningiomas, with a first statistical evaluation. MATERIALS AND METHODS The export of data included all cases of meningiomas recorded in the PELICAN application until July 2018. The PELICAN application is a Microsoft Excel file containing a software, written in Visual Basic for Applications, and used by the pathologist to create the report. The main clinical data were collected from the Hérault Register census form. Follow-up was systematically reported for atypical meningiomas. RESULTS Two hundred and ninety-five meningiomas were analyzed, including 250 grade I meningiomas, 42 grade II meningiomas, and 3 grade III meningiomas. Grade II meningiomas were characterized by a significantly higher proportion of men (P=0.002) and dural infiltration (P<0.001), a significant increase in the Ki-67 index (P<0.0001), and a significant decrease in progesterone receptor expression (P<0.001). In atypical meningiomas, a Ki-67 index of more than 20 % was significantly correlated with a shorter progression-free survival (P=0.032). CONCLUSION The PELICAN software is an easy-to-use tool that allows to generate standardized reports and feed a database, opening very interesting perspectives from an epidemiological and scientific point of view.
Collapse
Affiliation(s)
- Clémence Yguel
- Service d'anatomie et cytologie pathologiques, hôpital Central, CHRU de Nancy, 29, avenue du Maréchal-de-Lattre-de-Tassigny, 54000 Nancy, France
| | | | - Stéphanie Lacomme
- Centre de ressources biologiques BB-0033-00035, CHRU de Nancy, 54000 Nancy, France
| | - Sandra Lomazzi
- Centre de ressources biologiques BB-0033-00035, CHRU de Nancy, 54000 Nancy, France
| | - Emilie Lardenois
- Service d'anatomie et cytologie pathologiques, hôpital Central, CHRU de Nancy, 29, avenue du Maréchal-de-Lattre-de-Tassigny, 54000 Nancy, France
| | - Celso Pouget
- Service d'anatomie et cytologie pathologiques, hôpital Central, CHRU de Nancy, 29, avenue du Maréchal-de-Lattre-de-Tassigny, 54000 Nancy, France
| | - Luc Taillandier
- Service de neurologie, hôpital Central, CHRU de Nancy, 54000 Nancy, France
| | - Fabien Rech
- Service de neurochirurgie, hôpital Central, CHRU de Nancy, 54000 Nancy, France; Institut des neurosciences, Inserm U1051, 34091 Montpellier, France
| | - Valérie Rigau
- Service d'anatomie et cytologie pathologiques, CHU de Montpellier, 34000 Montpelier, France
| | - Jean-Michel Vignaud
- Service d'anatomie et cytologie pathologiques, hôpital Central, CHRU de Nancy, 29, avenue du Maréchal-de-Lattre-de-Tassigny, 54000 Nancy, France; Centre de ressources biologiques BB-0033-00035, CHRU de Nancy, 54000 Nancy, France; Inserm U1256, équipe 3 MIGB, NGERE, université de Lorraine, 54500 Vandœuvre-lès-Nancy, France
| | - Luc Bauchet
- Service de neurochirurgie, CHU de Montpellier, 34000 Montpellier, France
| | - Guillaume Gauchotte
- Service d'anatomie et cytologie pathologiques, hôpital Central, CHRU de Nancy, 29, avenue du Maréchal-de-Lattre-de-Tassigny, 54000 Nancy, France; Centre de ressources biologiques BB-0033-00035, CHRU de Nancy, 54000 Nancy, France; Inserm U1256, équipe 3 MIGB, NGERE, université de Lorraine, 54500 Vandœuvre-lès-Nancy, France.
| |
Collapse
|
11
|
Yguel C, Clauzon D, Lacomme S, Siat J, Lomazzi S, Lardenois E, Taillandier L, Vignaud JM, Gauchotte G. [Development and deployment of a standardized pathology report in lung cancer, basing on a data management software: The PELICAN software]. Ann Pathol 2019; 39:87-99. [PMID: 30736988 DOI: 10.1016/j.annpat.2018.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2018] [Revised: 11/05/2018] [Accepted: 12/09/2018] [Indexed: 11/28/2022]
Abstract
INTRODUCTION PELICAN (« Partager Éfficacement en Laboratoire les Informations des Comptes rendus ANatomopathologiques ») is a software which generates standardized reports and, in parallel, allows to automatically create a database that can be used for research purpose. This application has been used in our laboratory since 2014 for central nervous system tumors. The aim of this work was to extend it to another type of tumor, lung cancer. MATERIALS AND METHODS The content of the pathology reports was previously defined using various standards (Société Française de Pathologie, Institut National du Cancer, WHO Classification 2015, …). A double codification was used with SNOMED and ADICAP codes. The PELICAN application is a Microsoft Excel file containing a software specifically developed for pathology laboratories, written in Visual Basic for Applications and respecting the CDA-R2 standard. RESULTS After definition of the software specifications, a beta-version was installed in February 2018. After various updates, the 3.19 version was installed in July 2018. Almost all lung cancer surgical pathology reports are now generated with the PELICAN software; a total of 56 reports were validated at the time of writing this manuscript. The medical time for the generation of the report was globally the same or decreased for some pathologists. The secretarial time was greatly reduced. CONCLUSION The PELICAN software is an easy to use tool that allows to generate standardized reports in pulmonary pathology and to feed a database that can be easily used for statistical purposes.
Collapse
Affiliation(s)
- Clémence Yguel
- Service d'anatomie et cytologie pathologiques, hôpital Central, CHRU de Nancy, 29, avenue du Maréchal-De-Lattre de Tassigny, 54000 Nancy, France
| | - Dominique Clauzon
- Ingénieur consultant en solutions et développements informatiques, 54000 Nancy, France
| | - Stéphanie Lacomme
- Centre de ressources biologiques BB-0033-00035, CHRU de Nancy, 54000 Nancy, France
| | - Joelle Siat
- Service de chirurgie thoracique, CHRU de Nancy, 54500 Vandoeuvre-Les-Nancy, France
| | - Sandra Lomazzi
- Centre de ressources biologiques BB-0033-00035, CHRU de Nancy, 54000 Nancy, France
| | - Emilie Lardenois
- Service d'anatomie et cytologie pathologiques, hôpital Central, CHRU de Nancy, 29, avenue du Maréchal-De-Lattre de Tassigny, 54000 Nancy, France
| | - Luc Taillandier
- Service de neurologie, hôpital Central, CHRU de Nancy, 54000 Nancy, France
| | - Jean-Michel Vignaud
- Service d'anatomie et cytologie pathologiques, hôpital Central, CHRU de Nancy, 29, avenue du Maréchal-De-Lattre de Tassigny, 54000 Nancy, France; Centre de ressources biologiques BB-0033-00035, CHRU de Nancy, 54000 Nancy, France; INSERM U1256, équipe 3 MIGB, NGERE, université de Lorraine, 54500 Vandoeuvre-Les-Nancy, France
| | - Guillaume Gauchotte
- Service d'anatomie et cytologie pathologiques, hôpital Central, CHRU de Nancy, 29, avenue du Maréchal-De-Lattre de Tassigny, 54000 Nancy, France; Centre de ressources biologiques BB-0033-00035, CHRU de Nancy, 54000 Nancy, France; INSERM U1256, équipe 3 MIGB, NGERE, université de Lorraine, 54500 Vandoeuvre-Les-Nancy, France.
| |
Collapse
|
12
|
Bellissen A, Bertrand M, Templier C, Lardenois E, Mortier L, Darras-Vercambre S. Maladie de Paget extra-mammaire secondaire multifocale. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|